Syd Johnson

发表

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Herren Wu, D. Pfarr, Syd Johnson, 2007, Journal of molecular biology.

Structural basis of West Nile virus neutralization by a therapeutic antibody

T. Oliphant, G. Nybakken, D. Fremont, 2005, Nature.

Use of a Whole Genome Approach To Identify Vaccine Molecules Affording Protection against Streptococcus pneumoniae Infection

Theresa M. Wizemann, R. Lathigra, M. Hanson, 2001, Infection and Immunity.

Chikungunya Viruses That Escape Monoclonal Antibody Therapy Are Clinically Attenuated, Stable, and Not Purified in Mosquitoes

M. Diamond, S. Higgs, A. Legasse, 2014, Journal of Virology.

CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.

Steve Burke, J. Stavenhagen, H. Inzunza, 2006, Blood.

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

J. Stavenhagen, Syd Johnson, S. Burke, 2007, Cancer research.

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

P. Moore, J. Stavenhagen, Syd Johnson, 2011, Breast Cancer Research.

Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

P. Moore, Syd Johnson, S. Burke, 2012, Clinical Cancer Research.

Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice.

Syd Johnson, T. Maclachlan, R. Garman, 2012, Toxicological sciences : an official journal of the Society of Toxicology.

Cancer Therapy : Preclinical Development of an Fc-Enhanced Anti – B 7-H 3 Monoclonal Antibody with Potent Antitumor Activity

P. Moore, Syd Johnson, S. Burke, 2012 .

Monoclonal antibodies capable of discriminating the human inhibitory Fcγ‐receptor IIB (CD32B) from the activating Fcγ‐receptor IIA (CD32A): biochemical, biological and functional characterization

J. Stavenhagen, Syd Johnson, S. Burke, 2007, Immunology.

IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB.

Syd Johnson, J. Cambier, S. Koenig, 2010, Immunology letters.

Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice

R. Purcell, S. Leppla, Syd Johnson, 2011, Critical care medicine.

Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells

P. Moore, Syd Johnson, J. Nordstrom, 2015, PLoS pathogens.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016, Journal for ImmunoTherapy of Cancer.

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms

O. Elemento, A. Elia, P. Circosta, 2017, Oncoimmunology.

The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1

C. Nelson, Soila Sukupolvi-Petty, D. Fremont, 2010, PLoS pathogens.

An Anti-H5N1 Inﬂuenza Virus FcDART Antibody Is a Highly Efﬁcacious Therapeutic Agent and Prophylactic against H5N1 Inﬂuenza Virus Infection

R. Webster, R. Webby, Syd Johnson, 2015 .

Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.

F. Gao, F. Gao, J. Dipersio, 2016, Blood.

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates

P. Moore, Syd Johnson, S. Burke, 2015, Science Translational Medicine.

Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer

James R. Apgar, L. Mosyak, P. Moore, 2016, Antibodies.

Nonclinical Evaluation of GMA 161 — An Antihuman CD 16 ( Fc c RIII ) Monoclonal Antibody for Treatment of Autoimmune Disorders in CD 16 Transgenic Mice

Syd Johnson, T. Maclachlan, R. Garman, 2011 .

Capturing a Flavivirus Pre-Fusion Intermediate

D. Fremont, M. Diamond, M. Rossmann, 2009, PLoS pathogens.

MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies

P. Moore, Syd Johnson, S. Burke, 2016, Clinical Cancer Research.

MGD011, Humanized CD19 x CD3 DART® Protein with Enhanced Pharmacokinetic Properties, Demonstrates Potent T-Cell Mediated Anti-Tumor Activity in Preclinical Models and Durable B-Cell Depletion in Cynomolgus Monkeys Following Once-a-Week Dosing

P. Moore, Syd Johnson, S. Burke, 2014 .

Novel Applications of Bispecific DART® Proteins

P. Moore, Syd Johnson, B. Barat, 2013 .

Abstract 1201: Anti-B7-H3 antibody-drug conjugates as potential therapeutics for solid cancer

P. Moore, Syd Johnson, S. Koenig, 2016 .

MYELOID NEOPLASIA Targeting CD 123 in acute myeloid leukemia using a T-cell – directed dual-af fi nity retargeting platform

F. Gao, F. Gao, J. Dipersio, 2015 .

Structural Basis of Differential Neutralization of DENV-1 Genotypes by an Antibody that Recognizes a Cryptic Epitope

Michael S. Diamond, S. Kyle Austin, Daved H. Fremont, 2012, PLoS pathogens.

Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus

Chris Doane, G. Ebel, L. Kramer, 2005, Nature Medicine.

University of Groningen Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus Pal,

D. Fremont, T. Pierson, M. Diamond, 2013 .

Abstract 3636: Potent antitumor activity of duvortuxizumab, a CD19 x CD3 DART® molecule, in lymphoma models

Syd Johnson, Dana E. Cullen, L. Luistro, 2017 .

Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters.

M. Diamond, Hong Wang, Syd Johnson, 2006, The Journal of infectious diseases.

University of Groningen Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus Pal,

D. Fremont, T. Pierson, M. Diamond, 2013 .

Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2

R. Rico-Hesse, Soila Sukupolvi-Petty, D. Fremont, 2010, Journal of Virology.